Adverse reactions to methylphenidate treatment for attention-deficit/ hyperactivity disorder: Structure and associations with clinical characteristics and symptom control

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 6, 2009, Pages 683-690

  Sonuga Barke, Edmund J S ^a,b   Coghill, David ^c   Wigal, Timothy ^d   Debacker, Marc ^e   Swanson, James ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; METHYLPHENIDATE; PLACEBO;

ANXIETY; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDUCED HEADACHE; EMOTION; EMOTIONAL DISORDER; EUPHORIA; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SLEEP; SLEEP DISORDER; STOMACH PAIN; TASK PERFORMANCE; THERAPY EFFECT; TIC;

APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; EXPRESSED EMOTION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SLEEP; TREATMENT OUTCOME;

EID: 77049104531     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0024     Document Type: Article

References (31)

1. Aman MG, Arnold LE, Ramadan Y, Witwer A, Lindsay R, McDougle CJ, Posey DJ, Swiezy N, Kohn A, McCracken JT, Shah B, Cronin P, McGough J, Lee JSY, Scahill L, Martin A, Koenig K, Carroll D, Young C, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Chuang S, Davies M, Robinson J, McMahon D: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274, 2005.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
3. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJS, Taylor E: Longacting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Europ Child Adolesc Psychiatr 15:476-495, 2006.
4. Barkley RA, Mcmurray MB, Edelbrock CS, Robbins K: Side-effects of methylphenidate in children with attention-deficit hyperactivity disorder-A Systemic, placebo-controlled evaluation. Pediatrics 86:184-192, 1990.
5. Efron D, Jarman F, Barker M: Side Effects of methylphenidate and dexamethylphenidate etamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100:662-666, 1997.
6. Graham J, Coghill D: Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder-Epidemiology, prevention and management. CNS Drugs 22:213-237, 2008.
7. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 40:180-187, 2001a.
8. Greenhill LL, Vitiello B, Abikoff H, Levine J, March JS, Riddle MA, Capasso L, Cooper T, Davies M, Fisher P, Findling RL, Fried J, Labellarte M, McCracken J, McMahon DJ, Robinson J, Skrobala AM, Scahill L, Walkup J, Zito J: Improving the methods for evaluating the safety of psychotropic medications in children and adolescents. Curr Ther Res Clin Exp 62:873-1844, 2001b.
9. Jensen PS, Arnold LE, Richters JE, Severe JB, Vereen D, Vitiello B, Schiller E, Hinshaw SP, Elliott GR, Conners CK, Wells KC, March J, Swanson J, Wigal T, Cantwell DP, Abikoff HB, Hechtman L, Greenhill LL, Newcorn JH, Pelham WE, Hoza B, Kraemer HC: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder-The multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1088-1096, 1999.
10. Karabekiroglu K, Yazgan YM, Dedeoglu C: Can we predict shortterm side effects of methylphenidate immediate-release? Int J Psychiatr Clin Pract 12:48-54, 2008.
11. Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P, Erbe R, Pelham WE, Epstein LH: Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J Child Adolesc Psychopharmacology 19:127-136, 2009.
12. Levine J, Schooler NR: General versus specific inquiry with SAFTEE. J Clin Psychopharmacol 12:448, 1992.
13. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M, Chuang S, Wigal T, Wigal S, Posner K, Skrobala A, Kastelic E, Ghuman J, Cunningham C, Shigawa S, Moyzis R, Vitiello B: Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatr 45:1314-1322, 2006.
14. Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T: Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Cons Clin Psych 71:540-552, 2003.
15. Rapport MD, Kofler MJ, Coiro MM, Raiker JS, Sarver DE, Alderson M: Unexpected effects of methylphenidate in attention-deficit/ hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children. J Child Adolesc Psychopharmacol 18:237-247, 2008.
16. Sonuga-Barke EJS, Swanson J, Coghill D, DeCory, H, Hatch S: Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28, 2004.
17. Sonuga-Barke E, Coghill D, Markowitz J, Swanson J, Vandenberghe M, Hatch S: Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatr 46:701-710, 2007.
18. Sonuga-Barke EJS, Van Lier P, Swanson JM, Coghill D, Wigal S, Vandenberghe M, Hatch S: Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder: A growth mixture modelling analysis. Eur Child Adolesc Psychiatr 17:245-254, 2008.
19. Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B and Concerta Study Group: Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatr 45:527-537, 2006.
20. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 112:E404-E413, 2003.
21. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH: Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30:1374-1382, 2005.
22. Swanson JM: School-based assessments and interventions for ADD students. Irvine, CA: KC Publishing, 1992.
23. Swanson J, Wigal S, Greenhill L, Browne R, Waslick B, Lerner M, Williams L, Flynn D, Agler D, Crowley K, Fineberg E, Regino R, Baren M, Cantwell D: Objective and subjective measures of pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled analog classroom setting. Psychopharmacol Bull 34:55-60, 1998.
24. Swanson, J Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, COMACS Study Group: A comparison of two extended release preparations of methylphenidate; pharmacodynamic effects across the day. Pediatrics 113:e205-e215, 2004.
25. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BSG, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND: Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatr 46:1015-1027, 2007.
26. Taylor EA, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A: European Guidelines for Hyperkinetic Disorder- first upgrade. European Child & Adolescent Psychiatry 13(Suppl 1):7-30, 2004.
27. Vitiello B: Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin North Am 17:459, 2008.
28. Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O'Connor B, Majumdar A, Verley J, Hoffman MT, Massetti GA, Burrows-MacLean L, Fabiano GA, Waschbusch DA, Chacko A, Arnold FW, Walker KS, Garefino AC, Robb JA: The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol 18:573-588, 2008.
29. Weber P, Bubl R, Lutschg J: Side effects of methylphenidate in children. Prevalence and associated factors. Monatsschrift Kinderheilkunde 151:399-404, 2003.
30. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A: Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatr 45:1294-1302, 2006.
31. Wolraich ML, McGuinn L, Doffing M: Treatment of attention deficit hyperactivity disorder in children and adolescents-Safety considerations. Drug Safety 30:17-26, 2007.